Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 8.5% IN PLASTIC CONTAINER vs PREMASOL 10% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
TRAVASOL 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral nutrition.
Provides essential amino acids for protein synthesis and maintenance of nitrogen balance.
Total parenteral nutrition in patients with inadequate oral or enteral intake,Protein calorie malnutrition,Catabolic states (e.g., burns, major surgery, trauma)
Parenteral nutrition for patients unable to meet nutritional requirements orally or enterally,Treatment of negative nitrogen balance in catabolic states
Intravenous administration as total parenteral nutrition: typical adult dose is 8.5% amino acid solution at 0.8-1.5 g protein/kg/day, infused continuously or cyclically.
1-2 g/kg/day intravenously as a continuous infusion or in divided doses; typical starting dose for adults with normal renal function: 1 g/kg/day.
Not applicable; constituent amino acids have individual half-lives (e.g., 0.5–2 hours for most L-amino acids) but overall elimination follows zero-order kinetics during continuous infusion. Clinically, infusion rate determines steady-state concentrations.
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for most amino acids, reflecting rapid metabolism and distribution. Clinically, this supports continuous infusion to maintain plasma amino acid levels.
GFR 30-59 m L/min: reduce to 0.5-0.8 g protein/kg/day; GFR <30 m L/min: 0.4-0.5 g/kg/day; monitor BUN and electrolytes.
For GFR 30-59 m L/min: start at 0.8 g/kg/day and titrate based on protein tolerance; for GFR 15-29 m L/min: 0.6 g/kg/day; for GFR <15 m L/min or dialysis: 0.4-0.6 g/kg/day with careful monitoring.
Not for use in patients with severe hepatic failure, severe uremia, or inborn errors of amino acid metabolism. Risk of hyperammonemia and metabolic acidosis.
Amino acid solutions like TRAVASOL 8.5% are essential for maternal nutrition in pregnancy; however, there are no well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Use during pregnancy only if clearly needed. First trimester: potential risks are not established; avoid unless maternal benefit outweighs unknown fetal risk. Second and third trimesters: may be used cautiously for nutritional support, with monitoring for electrolyte imbalances and fluid overload in the fetus.
PREMASOL 10% (amino acid injection) is not teratogenic in animal studies at clinically relevant doses. In humans, no clear teratogenic risk has been identified with standard use; however, data are limited. First trimester rapid cell division and organogenesis may be affected by severe maternal metabolic disturbances. Second and third trimesters: risk is primarily related to maternal undernutrition or metabolic derangements rather than direct fetal toxicity. Use only when clearly indicated.
TRAVASOL 8.5% is a crystalline amino acid solution used for parenteral nutrition. It contains 8.5% amino acids and provides 85 g protein/L. It is hypertonic (approx. 880 m Osm/L) and must be administered via a central line to avoid thrombophlebitis. Shake container vigorously before use; do not use if cloudy or precipitate present. Do not add medications directly to the plastic container without checking compatibility. Protect from light; do not freeze. Use dedicated IV line without simultaneous blood products due to risk of agglomeration.
Premasol 10% is a crystalline amino acid solution used for parenteral nutrition. Always check for incompatibilities with other IV additives; calcium and phosphate must be added in correct ratio to avoid precipitation. Monitor serum electrolytes, renal function, and ammonia levels regularly. Use with caution in patients with hepatic or renal impairment due to risk of metabolic disturbances. Ensure central line placement for hypertonic solutions to prevent phlebitis.
No interactions on record
No interactions on record
TRAVASOL 8.5% IN PLASTIC CONTAINER and PREMASOL 10% IN PLASTIC CONTAINER are distinct pharmacological agents. TRAVASOL 8.5% IN PLASTIC CONTAINER belongs to the Amino Acid Solution class and is primarily used for Total parenteral nutrition in patients with inadequate oral or enteral intakeProtein calorie malnutritionCatabolic states (e.g., burns, major surgery, trauma). PREMASOL 10% IN PLASTIC CONTAINER belongs to the Amino Acid Solution class and is primarily used for Parenteral nutrition for patients unable to meet nutritional requirements orally or enterallyTreatment of negative nitrogen balance in catabolic states. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TRAVASOL 8.5% IN PLASTIC CONTAINER carries a safety status of Category C, whereas PREMASOL 10% IN PLASTIC CONTAINER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Amino acids are metabolized via deamination, transamination, and oxidative pathways primarily in the liver. Nitrogen is incorporated into urea via the urea cycle.
Amino acids are metabolized via transamination, deamination, and urea cycle in the liver.
Renal elimination of nitrogenous waste products (urea, ammonia) derived from amino acid metabolism; biliary/fecal excretion negligible. In healthy adults, >90% of infused amino nitrogen is ultimately excreted as urea in urine.
Amino acids in Premasol 10% are metabolized and the nitrogen is eliminated primarily as urea via renal excretion (80-90%). A small fraction is excreted in feces (5-10%) and as ammonia in urine. Biliary excretion is negligible.
Minimal (<10%) for individual amino acids; binding to albumin or other plasma proteins is negligible. Transport is primarily via specific carrier-mediated processes.
Amino acids are not significantly bound to plasma proteins; protein binding is less than 10% for most amino acid components.
Approximately 0.3–0.5 L/kg for total amino acids, reflecting distribution into total body water and intracellular compartments. Higher distribution for branched-chain amino acids (leucine, isoleucine, valine) into muscle.
Volume of distribution for amino acids in Premasol 10% ranges from 0.2 to 0.4 L/kg, approximating total body water, indicating distribution into extracellular and intracellular compartments.
Intravenous: 100% (complete). Not administered orally; if taken orally, amino acids are absorbed with bioavailability >90% but first-pass metabolism reduces systemic availability of some (e.g., glutamine, alanine).
Bioavailability is 100% for intravenous administration; oral or intramuscular routes are not applicable as Premasol 10% is intended for IV use only.
Child-Pugh Class A: no adjustment; Class B: reduce to 0.6-0.8 g protein/kg/day; Class C: 0.4-0.6 g/kg/day; avoid in hepatic encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, maximum 0.5 g/kg/day or avoid.
Weight-based: 1.0-2.5 g protein/kg/day intravenously, adjusted for age and clinical status; neonates: 1.5-3.0 g/kg/day.
0.5-2 g/kg/day intravenously; for preterm infants: start at 0.5 g/kg/day; for term infants: 1 g/kg/day; for children: 1-2 g/kg/day based on clinical need.
Start at lower end of adult range (0.8-1.0 g/kg/day) and titrate based on renal function and metabolic tolerance; monitor fluid and electrolyte balance closely.
Start at lower end of adult dose (0.8-1 g/kg/day) and adjust based on renal function and fluid status; monitor for fluid overload and electrolyte imbalances.
Not for use in patients with inborn errors of amino acid metabolism, hepatic failure, or severe metabolic acidosis.
Monitor fluid and electrolyte status, acid-base balance, and blood glucose. Risk of hyperglycemia, hyperammonemia, and metabolic acidosis. Use with caution in renal insufficiency, hepatic impairment, and heart failure.
Hypersensitivity to any component, inborn errors of amino acid metabolism, hepatic failure, severe metabolic acidosis, anuria, and galactosemia (if product contains galactose).
There are no direct food interactions as this is an intravenous solution. However, oral food intake is usually restricted or absent during parenteral nutrition therapy. Monitor for refeeding syndrome in severely malnourished patients.
No oral food interactions as this is administered intravenously. However, warn patients not to ingest anything orally unless advised by the medical team, as they may be on nil per os (NPO) status.
TRAVASOL 8.5% is a sterile, hypertonic amino acid solution for intravenous infusion. It is unknown whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRAVASOL 8.5% is administered to a nursing woman. The molecular weight of amino acids (< 200 Da) suggests potential for transfer into breast milk, but clinical significance is low due to endogenous presence. M/P ratio: not established.
Amino acids are normal constituents of breast milk; supplementation with intravenous amino acids increases maternal plasma levels and may increase milk amino acid content. The M/P ratio is not established. Limited data suggest no adverse effects in breastfed infants. Use with caution in lactating women only if clearly needed.
No specific dose adjustments are recommended during pregnancy based on pharmacokinetic changes. However, pregnancy increases plasma volume and renal blood flow, potentially altering amino acid clearance. Dose should be individualized based on maternal nutritional status, clinical response, and laboratory monitoring. Avoid overhydration and hyperglycemia. Use with caution in preeclampsia or gestational diabetes.
No specific dose adjustment required for pregnancy. However, monitor for fluid overload due to increased plasma volume and adjust infusion rate accordingly. Consider increased nitrogen requirements, typically not exceeding 2 g/kg/day. Use with caution in preeclampsia or renal impairment.
This medication is given through a vein to provide protein calories when you cannot eat normally.,Your healthcare provider will monitor your blood sugar, kidney, and liver function regularly.,Tell your doctor if you experience fever, chills, flushing, or injection site pain.,Do not stop or adjust the infusion rate without consulting your healthcare team.,If you have diabetes, your blood glucose may rise; follow your management plan.
This medication provides nutrition through your vein because you cannot eat or absorb food normally.,Report any signs of infection at the IV site, such as redness, swelling, or pain.,You may need frequent blood tests to monitor your nutrition and organ function.,Do not stop or change the infusion rate without consulting your healthcare provider.,Inform your doctor if you have a history of liver or kidney problems, or if you are pregnant or breastfeeding.